Bioatla Inc (BCAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioatla Inc (BCAB) has a cash flow conversion efficiency ratio of 0.316x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.88 Million) by net assets ($-31.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bioatla Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Bioatla Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bioatla Inc (BCAB) financial obligations for a breakdown of total debt and financial obligations.
Bioatla Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioatla Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trainline Plc
LSE:TRN
|
0.441x |
|
elumeo SE
XETRA:ELB
|
0.087x |
|
Sama Resources Inc.
V:SME
|
-0.002x |
|
MYMBN Berhad
KLSE:0280
|
-0.085x |
|
Strategic Energy Resources Ltd
AU:SER
|
-0.024x |
|
Quince Therapeutics, Inc.
NASDAQ:QNCX
|
-9.375x |
|
Sarthak Metals Limited
NSE:SMLT
|
0.009x |
|
Concord Medical Services Holdings
NYSE:CCM
|
0.009x |
Annual Cash Flow Conversion Efficiency for Bioatla Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Bioatla Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see BCAB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.27 Million | $-71.94 Million | -5.043x | -242.63% |
| 2023-12-31 | $70.67 Million | $-104.02 Million | -1.472x | -193.54% |
| 2022-12-31 | $180.34 Million | $-90.42 Million | -0.501x | -69.90% |
| 2021-12-31 | $210.82 Million | $-62.21 Million | -0.295x | -70.54% |
| 2020-12-31 | $209.97 Million | $-36.33 Million | -0.173x | -200.49% |
| 2019-12-31 | $-56.01 Million | $-9.64 Million | 0.172x | -86.13% |
| 2018-12-31 | $-28.45 Million | $-35.32 Million | 1.242x | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer … Read more